drugset

drugset / Trial / NCT03193502

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

NCT03193502 ↗

Phase 3 Unknown 40 enrolled Tanta University

NaSingle-groupOpen-labelTreatment

Summary

-Rivaroxaban is factor Xa inhibitor

Timeline

Start: 2014-05-01
Primary completion: 2020-07
Completion: 2020-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivaroxaban	Other / unclassified	—	—

Indications